Prosensa Strengthens its Management Team and Supervisory Board with Key Appointments

Prosensa Strengthens its Management Team and Supervisory Board with Key
Appointments

Preparing for anticipated launch of lead compound for DMD

Leiden, The Netherlands, June 30, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding
N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare
diseases with a high unmet medical need, today announced the appointment of
Willem W. van Weperen to the new position of chief commercial officer and the
addition of Dr. Annalisa Jenkins to its Supervisory Board.

With more than two  decades of experience  at Genzyme and  GSK and his  recent 
leadership of Dutch to-BBB as CEO, Mr. van Weperen brings significant business
operational and commercial expertise to Prosensa in advance of an  anticipated 
launch of the company's first product  for the treatment of Duchenne  muscular 
dystrophy (DMD). 

Hans Schikan, CEO of Prosensa said, "We expect Willem to play a critical  role 
at Prosensa as  we move from  a research  and development stage  company to  a 
commercial organization. His knowledge and experience will be invaluable as we
build the  infrastructure  to support  the  anticipated launch  of  our  first 
product for treating boys with DMD."

Prior to his role at  to-BBB, Mr. van Weperen spent  15 years at Genzyme in  a 
number of senior management  and commercial positions at  both a national  and 
international level. He joined Genzyme in  1994 as medical affairs manager  in 
Europe. Subsequently, he worked as Area Manager Therapeutics for the  Benelux, 
responsible for  sales  and marketing  of  Genzyme's orphan  disease  products 
following which he  took on the  role as European  Marketing Director for  the 
Company's LSD/Thyrogen products. Since 2003, he assumed global  responsibility 
for marketing in the rare genetic disease business unit in Genzyme's worldwide
headquarters in Cambridge,  MA. Most  recently, he  led Genzyme's  Netherlands 
organization in Naarden. At Genzyme, he oversaw and significantly contributed
to  several  global  launches  of  products  in  the  company's  rare  disease 
portfolio.

"I'm thrilled to be joining Prosensa at such an exciting and pivotal time  for 
the company and look forward to applying my expertise in commercializing  rare 
disease drugs to  potentially launching  one of  the first  products to  treat 
DMD," said Mr. van Weperen.

Dr. Jenkins joins  Prosensa's Supervisory  Board with  more than  25 years  of 
experience in the healthcare sector. In her most recent role as Head of Global
Research and Development and Executive  Vice President at Merck Serono,  which 
she has  held since  October 2013,  she was  responsible for  building  global 
development,   research   and   medical   capabilities,   spanning   research, 
development,  global  regulatory  and  clinical  development  in  addition  to 
medical  affairs  and  patient  access.  She  joined  the  company  in  2011, 
previously serving as Executive Vice President Global Development and Medical.
Prior to joining Merck  Serono, Dr. Jenkins held  various regional and  global 
roles with  Bristol-Myers Squibb  since  1997, most  recently as  Senior  Vice 
President, Global Medical Affairs.

"We are delighted  to welcome  Annalisa to Prosensa's  Supervisory Board.  Her 
extensive experience in research and clinical development and medical  affairs 
for Merck Serono and Bristol Myers  Squibb, which are amongst the top  pharma 
companies in the  world, will bring  valuable insights  to us as  we take  the 
company to the next level," said David Mott, Chairman of the Supervisory Board
at Prosensa.

Dr. Jenkins began her career as a Medical Officer with the British Royal  Navy 
after graduating  in  Medicine  from St.  Bartholomew's  Hospital  London  and 
training in Cardiovascular Medicine in the UK National Health Service.

"I am excited to join Prosensa at such a significant moment in the company's
history and look forward to working alongside a world-class team with
exceptional leadership in rare diseases," saidDr. Jenkins. "With such an
extensive research and development pipeline in DMD, I hope to integrate my
expertise in global R&D as Prosensa continues to advance its portfolio of
innovative exon-skipping technology."

The appointment of Dr. Annalisa Jenkins will be subject to shareholders'
approval at the next shareholders' meeting, scheduled for August 20, 2014.

Notes to editors

About Prosensa Holding N.V.

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the
discovery and development of RNA-modulating therapeutics for the treatment of
genetic disorders. Its primary focus is on rare neuromuscular and
neurodegenerative disorders with a large unmet medical need, including
Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington's
disease.

Prosensa's current portfolio includes six compounds for the treatment of DMD,
all of which have received orphan drug status in the United States and the
European Union. The compounds use an innovative technique called exon-skipping
to provide a personalized medicine approach to treat different populations of
DMD patients. www.prosensa.com

CONTACT: Celia Economides
         Prosensa Holding N.V.
         Sr Director IR & Corporate Communications
         c.economides@prosensa.nl

Prosensa Holding B.V. Logo
 
Press spacebar to pause and continue. Press esc to stop.